Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21523354 | 1.00 | KMT2A (0.46) | KMT2APOLBL3MBTL1ACECYP1A2 | |
| SCHEMBL20263696 | 1.00 | KMT2A (0.46) | KMT2APOLBL3MBTL1ACECYP1A2 | |
| SCHEMBL24204924 | 0.90 | L3MBTL1 (0.45) | KMT2APOLBL3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL20710289 | 0.90 | L3MBTL1 (0.45) | KMT2APOLBL3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL9236716 | 0.89 | KMT2A (0.53) | KMT2APOLBL3MBTL1NOD1 | |
| SCHEMBL24235669 | 0.89 | KMT2A (0.53) | KMT2APOLBL3MBTL1NOD1 | |
| SCHEMBL9088322 | 0.89 | KMT2A (0.53) | KMT2APOLBL3MBTL1NOD1 | |
| SCHEMBL14720047 | 0.88 | L3MBTL1 (0.57) | KMT2APOLBL3MBTL1ACECYP1A2 | |
| SCHEMBL20341486 | 0.87 | KMT2A (0.46) | KMT2APOLBL3MBTL1CYP1A2P2RY12 | |
| SCHEMBL21668640 | 0.87 | POLB (0.57) | KMT2APOLBL3MBTL1ACECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-03-27 | — | — | US | disclosed |
| US-12144865-B2 | Antibody drug conjugates with enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-11-19 | — | — | US | disclosed |
| US-12059472-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-13 | — | — | US | disclosed |
| WO-2024105205-A1 | ANTIBODY-DRUG CONJUGATES (A2DCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-23 | — | — | WO | disclosed |
| US-20240043379-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-02-08 | — | — | US | disclosed |
| US-20230338559-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-11660351-B2 | Antibody drug conjugates (ADCs) having enzymatically cleavable groups | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-30 | — | — | US | disclosed |
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-02-09 | — | — | US | disclosed |
| US-11478554-B2 | Antibody drug conjugates (ADCS) having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-10-25 | — | — | US | disclosed |
| CN-114917361-A | Antibody Drug Conjugates (ADC) and antibody prodrug conjugates (APDC) with enzyme cleavable groups | 拜耳医药股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20220016258-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-01-20 | — | — | US | disclosed |
| US-11123439-B2 | Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-09-21 | — | — | US | disclosed |
| US-20190351066-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-11-21 | — | — | US | disclosed |
| US-20190328897-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-31 | — | — | US | disclosed |
| US-20190077752-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-14 | — | — | US | disclosed |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12059472-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | LGMN, BUB1B, KIF15 | KMT2A 2874/4885POLB 470/4885L3MBTL1 626/4885 |
| US-11123439-B2 | Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups | KIFC1, KIF2C, KIF5B | KMT2A 1431/4885POLB 2784/4885L3MBTL1 4061/4885 |
| US-20190328897-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | VCAM1, FCGR1A, DNPEP | KMT2A 1466/4885POLB 2060/4885L3MBTL1 3443/4885 |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | KMT2A 2705/4885POLB 423/4885L3MBTL1 1454/4885 |
| US-20190351066-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | LGMN, BUB1B, KIF15 | KMT2A 2874/4885POLB 470/4885L3MBTL1 626/4885 |
| US-11478554-B2 | Antibody drug conjugates (ADCS) having enzymatically cleavable groups | VCAM1, FCGR1A, DNPEP | KMT2A 1466/4885POLB 2060/4885L3MBTL1 3443/4885 |
| US-20220016258-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | VCAM1, FCGR1A, DNPEP | KMT2A 1466/4885POLB 2060/4885L3MBTL1 3443/4885 |
| US-20240043379-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BUB1B, KIF5B, TK1 | KMT2A 2705/4885POLB 423/4885L3MBTL1 1454/4885 |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | KIFC1, KIF2C, KIF5B | KMT2A 1431/4885POLB 2784/4885L3MBTL1 4061/4885 |
| US-20230338559-A1 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | VCAM1, FCGR1A, DNPEP | KMT2A 1466/4885POLB 2060/4885L3MBTL1 3443/4885 |
| US-20190077752-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BUB1B, KIF5B, TK1 | KMT2A 2705/4885POLB 423/4885L3MBTL1 1454/4885 |
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | KIF18B, KIF18A, KIF5B | KMT2A 1659/4885POLB 1295/4885L3MBTL1 2472/4885 |
| US-11660351-B2 | Antibody drug conjugates (ADCs) having enzymatically cleavable groups | VCAM1, FCGR1A, DNPEP | KMT2A 1466/4885POLB 2060/4885L3MBTL1 3443/4885 |
| US-12144865-B2 | Antibody drug conjugates with enzymatically cleavable groups | KIFC1, KIF2C, KIF5B | KMT2A 1816/4885POLB 2069/4885L3MBTL1 3813/4885 |
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | KIFC1, KIF2C, KIF5B | KMT2A 1431/4885POLB 2784/4885L3MBTL1 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.